Aeglea BioTherapeutics, Inc.(AGLE) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Waltham, Mass, August 5, 2025 - Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD") and other immune-mediated diseases, today announced its second quarter 2025 financial results and provided program and corporate updates. "Spyre is entering a ...